Clinical Trial Update: Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease [Phase 3]

View source ↗

Summary

A Phase III clinical trial evaluating Telitacicept injection for connective tissue disease-associated interstitial lung disease (CTD-ILD); the study is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Connective Tissue Disease-associated Interstitial Lung Disease

Drugs mentioned

• Telitacicept

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: CTD-ILD | Phase 3 | Status: NOT_YET_RECRUITING